EASYPLUS MINI MASTERDRIVER SELF MONITORING BLOOD GLUCOSE SYSTEM, MODEL EPS09009

K092887 · Eps Bio Technology Corp. · NBW · Oct 21, 2009 · Clinical Chemistry

Device Facts

• Record ID: K092887
• Device Name: EASYPLUS MINI MASTERDRIVER SELF MONITORING BLOOD GLUCOSE SYSTEM, MODEL EPS09009
• Applicant: Eps Bio Technology Corp.
• Product Code: NBW · Clinical Chemistry
• Decision Date: Oct 21, 2009
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 862.1345
• Device Class: Class 2

Indications for Use

The EasyPlus mini MasterDriver SMBG Test System is intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips or forearm. Testing is done outside the body (In Vitro diagnostic use). It is indicated for use at home (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control. The EasyPlus mini MasterDriver Meter is intended for the quantitative measurement of glucose in fresh capillary The Easy 160 min habert in on the fingertips or forearm. EasyPlus mini MasterDriver Blood Glucose Test Strips must be used with the EasyPlus mini MasterDriver Meter. Testing is done outside the body (In Vitro diagnostic use). rnust of dood with the Each nover the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control. The EasyPlus mini MasterDriver Blood Glucose Test Strips, are intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingerips or forearm. EasyPlus mini MasterDriver Blood in fresh oppliary while blood sen with the EasyPlus mini MasterDriver Blood Glucose Meter. Testing is done outside the body (In Vitro diagnostic use). They are indicated for use at home (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control. EasyPlus mini MasterDriver Glucose Control Solutions For use with the EasyPlus mini MasterDriver meter and EasyPlus mini MasterDriver Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results.

Device Story

System measures glucose in fresh capillary whole blood from fingertips or forearm; utilizes test strips and meter for in vitro diagnostic use. Operated by patients at home or healthcare professionals in clinical settings. Meter processes blood sample via test strip to provide quantitative glucose concentration. Output used by patients/clinicians to monitor diabetes control effectiveness. Includes control solutions for quality verification.

Clinical Evidence

Bench testing only. Studies included readability test, user performance evaluation, meter performance evaluation, meter software validation, PC software validation, data transmission accuracy test, drop test, vibration test, EMC test, and safety test. All verification and validation activities met predetermined acceptance criteria.

Technological Characteristics

In vitro diagnostic glucose test system; includes meter, test strips, and control solutions. Quantitative measurement principle. Intended for capillary whole blood samples.

Indications for Use

Indicated for self-monitoring of blood glucose levels in patients with diabetes.

Regulatory Classification

Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Submission Summary (Full Text)

{0}

SPECIAL 510(k): Device Modification

ODE Review Memorandum (Decision Making Document is Attached)

To: THE FILE

RE: DOCUMENT NUMBER: k092887

This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable (delete/add items as necessary):

1. The name and 510(k) number of the SUBMITTER'S previously cleared device. (For a preamendments device, a statement to this effect has been provided.) EasyPlus mini R13N Self-Monitoring Blood Glucose System (k091481) and GlucoManager Software (k091229)

2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).

3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.

This change was for: changing the physical appearance of the meter, changing the model name from EasyPlus mini R13N Self-Monitoring Blood Glucose System and combining GlucoManager Software into the meter. The EasyPlus mini Master Driver also includes a flash memory which can be downloaded into a PC.

4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, physical characteristics, analytes and performance characteristics. Studies include readability test, user performance evaluation, meter performance evaluation, meter software validation, PC software validation, data transmission accuracy test in software test, drop test, vibration test, EMC test, and safety test.

5. A Design Control Activities Summary which includes:

a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis. FMEA
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied
c) A declaration of conformity with design controls. The declaration of conformity should include:

i) A statement signed by the individual responsible, that, as required by the risk analysis, all verification and validation activities were performed by the designated individual(s) and the results demonstrated that the predetermined acceptance criteria were met, and
ii) A statement signed by the individual responsible, that the manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review.

6. A Truthful and Accurate Statement, a 510(k) Summary or Statement and the Indications for Use Enclosure (and Class III Summary for Class III devices).

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.